Purpose

The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation. Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm. - Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Fertilo for 30 hours. - Arm 2 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Medicult IVM for 30 hours.

Condition

Eligibility

Eligible Ages
Between 18 Years and 35 Years
Eligible Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Written informed consent. 2. Premenopausal, Age 18-35. 3. Body mass index (BMI) 21-40. 4. Candidate for IVF according to the ASRM definition (infertile for ≥12 months, require the use of donor sperm, or the inability to achieve a successful pregnancy based on a patient's medical, sexual, and reproductive history, age, physical findings, diagnostic testing, or any combination of those factors). 5. No contraindications to the use of oral contraceptive pills (OCP) or gonadotropins. 6. Plan to use embryos for transfer within 2 months of blastocyst cryopreservation. 7. Anti-mullerian hormone (AMH) ≥ 3 ng/mL within 6 months of Screening/Visit 1 or assessed at the screening visit. 8. Normal uterine cavity as assessed by hysteroscopy, hysterosalpingography or sonohysterography within 12 months of Screening/Visit 1 or assessed at the screening visit. 9. Having adequate visualization of both ovaries, without evidence of significant abnormality/pathology or major cyst documented by transvaginal ultrasound within 3 months of screening or assessed during screening period. 10. No endometriosis of American Fertility Society (AFS) grade 3 or 4 or presence of endometrioma. 11. Minimum of 1 month without treatment with either clomiphene citrate, GnRH agonist or gonadotropins prior to start of ovarian stimulation. 12. Have a male partner with semen analysis within the past 12 months prior to randomization considered adequate to proceed with intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If this criterion is not met, the subject can only be entered if donor sperm will be used.

Exclusion Criteria

  1. History of recurrent pregnancy loss (defined as >2 clinical pregnancies without live birth). 2. Baseline prolactin levels greater than 30 ng/ml 3. Male: requirement for retrograde ejaculation procedures or surgical sperm retrievals. 4. Any clinically relevant pathology that in the judgment of the investigator could impair embryo implantation or pregnancy continuation. 5. Use of preimplantation genetic testing (PGT) of oocytes, embryos, or transferred blastocysts during participation in the study. 6. Use of donated oocytes, embryos or blastocysts for this treatment cycle while participating in the study or use of oocytes, embryos, or blastocysts from a previous treatment cycle. 7. Participation in a concurrent clinical trial or in another investigational drug trial within the past 2 months.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Fertilo
Immature cumulus-oocyte complexes (COCs) are oocytes surrounded by cumulus cells that have not yet matured. The COCs are cultured in Fertilo coculture condition then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose.
  • Biological: Fertilo
    Fertilo is an engineered line of ovarian support cells that aid egg maturation.
Active Comparator
Medicult IVM®
Immature COCs are cultured in the standard IVM system MediCult IVM® then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose.
  • Device: Medicult IVM
    MediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes.

Recruiting Locations

Women's Specialty & Fertility Center
Clovis, California 93611
Contact:
Casey Study Coordinator
559-299-7700
cstorm@santehealth.net

HRC Fertility
Encino, California 91436
Contact:
Wendy Shubin, MPAS, PA-C
818-788-7288
clinicaltrialsENC@havingbabies.com

Florida Fertility Institute
Clearwater, Florida 33759
Contact:
Gayle Cameron
727-724-9730
gaylec@xxresearch.com

IVF Florida
Pembroke Pines, Florida 33026
Contact:
Karina Stroker
954-247-6200
karina.stroker@usfertility.com

Shady Grove Fertility
Rockville, Maryland 20850
Contact:
Joshua McKeeby
301-545-1423
sgfclinicalresearchteam@sgfertility.com

Columbia University Fertility Center
New York, New York 10019
Contact:
Stephanie Morgan
212-314-8837
sm3415@cumc.columbia.edu

Reach Fertility
Charlotte, North Carolina 28207
Contact:
Stephanie Graham, MS
704-343-4455
Stephanie.Graham@northcarolinafertility.com

Conceptions Fertility
Raleigh, North Carolina 27607
Contact:
Sofia Sequeira
919-782-5911
ccresearch@carolinaconceptions.com

Aspire Fertility Dallas
Addison, Texas 75001
Contact:
Study Coordinator
214-414-3806
adenson@aspirefertility.com

Aspire Fertility Austin
Austin, Texas 78705
Contact:
Butler
512-479-7979
abutler@aspirefertility.com

Care Fertility
Bedford, Texas 76022
Contact:
Michelle Evans
817-540-7070
michellee@embryo.net

Dallas Fort Worth Fertility Associates
Dallas, Texas 75231
Contact:
Jenny Patel
214-363-5965
thirdparty@dallasfertility.com

Aspire Fertility San Antonio
San Antonio, Texas 78528
Contact:
Sonam Study Coordinator
575-815-8206
Research@inceptionllc.com

Shady Grove Houston
Webster, Texas 77598
Contact:
Cara Barrier, RN
832-342-9129
cara.barrier@sgfertility.com

Utah Fertility Center
Pleasant Grove, Utah 84062
Contact:
Coral Halterman, RN
801-785-5100
coral.halterman@utahfertility.com

More Details

Status
Recruiting
Sponsor
Gameto, Inc.

Study Contact

Clinical Trials
512-535-1164
clinicaltrials@gametogen.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.